APA (7th ed.) Citation

Easaw, J. C., Lim, H. J., Karachiwala, H., Gill, S., Zhu, X., & Bateman, J. (2025). Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options. Current Oncology, 32(11), 648. https://doi.org/10.3390/curroncol32110648

Chicago Style (17th ed.) Citation

Easaw, Jacob C., Howard J. Lim, Hatim Karachiwala, Sharlene Gill, Xiaofu Zhu, and Justin Bateman. "Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options." Current Oncology 32, no. 11 (2025): 648. https://doi.org/10.3390/curroncol32110648.

MLA (9th ed.) Citation

Easaw, Jacob C., et al. "Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options." Current Oncology, vol. 32, no. 11, 2025, p. 648, https://doi.org/10.3390/curroncol32110648.